Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug tarlatamab takes on tough lung cancers

NCT ID NCT07016230

Recruiting now Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a drug called tarlatamab in 40 people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. The drug is given by IV and aims to shrink tumors. Researchers will also study blood and tumor samples to understand why some patients respond and others don't.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC/LOCALLY ADVANCED SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Gustave Roussy

    RECRUITING

    Villejuif, France

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tarlatamab

What this could lead to

If successful, this could provide a new treatment option for hard-to-treat small-cell lung cancer and related neuroendocrine cancers.

What could go wrong

This is a small, early-phase trial with only 40 participants. The drug may not shrink tumors or could cause serious side effects. Results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

medullary thyroid gland carcinoma Neoplasm Metastasis neuroendocrine carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC/LOCALLY ADVANCED HIGH-GRADE MTC METASTATIC/LOCALLY ADVANCED POORLY DIFFERENTIATED NEC METASTATIC/LOCALLY ADVANCED SMALL-CELL LUNG CANCER